Presage Biosciences

Presage Biosciences develops a technology platform to improve the cancer drug development process.

Launch date

Nov 2008

Employees

Market cap

Enterprise valuation

Seattle Washington (HQ)

Date	Investors	Amount	Round
Nov 2009	David Wu	N/A	Seed
Jun 2010	N/A	$4.0m	Series A
Aug 2011	N/A	$1.6m	Debt
Mar 2013	Takeda Ventures	$8.0m	Debt
Aug 2015	Takeda Ventures Celgene	$6.0m	Series D
Jul 2018	Takeda Ventures Bristol-Myers Squibb Celgene Takeda	$6.0m	Series D
Mar 2021	Takeda Ventures Takeda	$6.0m	Convertible
Mar 2021	Bristol-Myers Squibb LabCorp InHarv Partners	$7.0m	Late VC
Total Funding		$29.0m

Tech stackLearn more about the technologies and tools that this company uses.

Recent News about Presage Biosciences